Data from the OrigAMI-4 trial support the accelerated approval of amivantamab and hyaluronidase-lpuj for this HNSCC population.
|Videos|October 6, 2017
Aggressive Treatment De-Escalation Feasible in HPV-Positive Oropharyngeal Cancer?
Author(s)Daniel J. Ma, MD
This video highlights 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
Advertisement
In this video, Daniel J. Ma, MD, of the Mayo Clinic in Rochester, Minnesota, discusses 2-year results of a phase II study evaluating aggressive adjuvant chemoradiation dose de-escalation in HPV-positive oropharynx squamous cell carcinoma.
Ma presented results of the study (
Advertisement
Related to this article
Petosemtamab plus pembrolizumab cut the risk of death by 50% vs pembrolizumab alone in first-line recurrent or metastatic PD-L1–positive head and neck cancer.
Frontline iza-bren plus pembrolizumab yielded a 57.9% ORR in recurrent or metastatic HNSCC at 2.5 mg/kg, the dose chosen for phase 3 study.
A cisplatin-free pembrolizumab regimen yielded 65.1% laryngectomy-free survival rate at 2 years in SMART-KEY, missing significance vs historical controls.
Bhanu Prasad Venkatesulu, MBBS, MD, discussed why fewer radiation oncologists offer prostate brachytherapy and the patients for whom he still recommends it.
Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.
Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Amivantamab for Recurrent/Metastatic HNSCC
2
Setting Up an HDR Brachytherapy Program Amid a National Decline
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
16-Fraction PMRT With IMN Irradiation Noninferior in High-Risk Breast Cancer
5